DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology

Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Anticancer Bioscience Ltd., an innovative China-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology. The collaboration joins key European innovations in biomaterials and the pinnacle of Chinese drug research innovation emerging from the prestigious J. Michael Bishop Institute of Cancer Research, mentored by the year 1989 Noble prize winner Professor J. Michael Bishop.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH